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Abstract
We compared the efficacy and safety of low-molecular-weight heparins (LMWHs) in patients with cancer who are at low risk of
venous thromboembolism (VTE). Patients were treated by medical oncologists in Turkey at 15 sites, where they were enrolled
and followed up for a period of 12 months. Due to the study design, there was no specific treatment protocol for LMWH. Primary
end points were efficacy and the time to change in VTE status. Of the included 250 patients, 239 (95.6%), 176 (70.4%), 130 (52.0%),
and 91 (36.4%) completed their day 15, month 3, month 6, and month 12 visits, respectively. Number of patients treated with
enoxaparin, bemiparin, and tinzaparin were 133, 112, and 5, respectively. Anticoagulant therapy provoked thrombus resolution in
1.2% and 12.7% of patients using enoxaparin and bemiparin, respectively (P ¼ .004). Thrombus resolution was observed in 81
more patients at month 3 visit. This ratio was 35 (40.2%) of 87 and 46 (54.1%) of 85 patients administered enoxaparin and
bemiparin at the third visit, respectively (P ¼ .038). Thrombus resolution was observed in 21 more patients during month 6 visit.
This ratio was 5 (7.7%) of 65 and 15 (23.4%) of 64 patients administered enoxaparin and bemiparin at the fourth visit, respectively
(P ¼ .022). The LMWH was discontinued in only 2 patients due to gastrointestinal bleeding. This pioneering study shows
bemiparin is more effective than enoxaparin in thrombosis resolution and has a similar tolerability profile.
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Introduction
Venous thromboembolism (VTE) is an important cause of
death in patients with cancer. The estimated risk of VTE is 4
to 7 times higher among these patients compared to the normal
population.1,2 Venous thromboembolism mostly occurs in the
early months of chemotherapy.1-3 The incidence ranged from
8% to 19% depending on the tumor type. Tumors associated
with the highest VTE risks are hematologic cancers followed
by pancreatic, stomach, lung, ovarian, uterine, bladder, and
brain tumors.1 A significantly higher proportion of VTE events
was diagnosed in the outpatient setting compared to the inpa-
tient setting. In a retrospective observational study in the
United States, among 17.874 patients with cancer, 78% were
outpatients and 22% were inpatients.2 Low-molecular-weight
heparins (LMWHs), such as dalteparin, enoxaparin, tinzaparin,
and bemiparin, are drugs of choice for VTE treatment and
prevention because they enable outpatient treatment and elim-
inate the need for therapeutic monitoring in most patients.4,5
Few clinical studies have tested whether the clinical effects of
these drugs are comparable.
Patients with cancer have a prothrombotic state resulting
from the synergic activity of factors involved in the so-called
Virchow’s triad. Stasis of the blood is caused by bed rest or the
tumor compression; vascular injury is caused by intravasation
of cancer cells, drugs, or therapeutic devices; and blood hyper-
coagulability is due to the release of cancer cell procoagulant
factors, which affect the hemostasis process, including platelet
functions and clotting cascade.6 As a consequence, interactions
between cancer cell, host cell, and treatments activate the clot-
ting process and cause various clinical presentations, such as
abnormal laboratory results or massive thrombotic attacks.7
Treatment with LMWH is preferred compared to vitamin K
antagonist (VKA) in patients with cancer.5,8 The effect of sev-
eral LMWHs compared to VKA were evaluated in several
randomized studies. In the ESFERA study of 583 patients,
Santamarı´a et al assessed the clinical and economic outcomes
associated with bemiparin versus VKA.4 In Meyer et al’s study
of 146 patients with cancer, authors assessed whether a fixed
dose of enoxaparin is superior to oral warfarin.9 In LITE study
of 200 patients, assessing tinzaparin versus VKA, and CLOT
study of 672 patients, assessing dalteparin versus coumarin, we
showed LMWH was more effective and/or safer than VKAs in
patients with cancer.10,11 However, if LMWH is not recom-
mended, warfarin is an acceptable alternative for long-term
therapy.5,8 Patients with cancer with deep vein thrombosis
(DVT) or pulmonary embolism (PE) should be treated for a
minimum duration of 3 months with either LMWH or warfarin.
Low-molecular-weight heparin is recommended for the first 6
months of chronic treatment of proximal DVT or PE.5 And
CHEST VTE treatment guideline recommended extended
anticoagulant therapy over 3 months of therapy in patients with
DVT or PE and active cancer.8 Anticoagulation for an indefi-
nite duration should be considered in patients with active can-
cer. Since the chronic treatment of VTE with LMWH has not
been evaluated in clinical trials of patients with cancer longer
than 6 months, the decision to continue LMWH beyond 6
months or to switch to warfarin therapy should be based on
clinical judgment.5,12
In the present observational study, we compared the effec-
tiveness and safety of available LMWHs (enoxaparin, bemi-
parin, or tinzaparin) selected based on clinician’s judgment
in outpatients with cancer who had low probability risk of
developing VTE.
Methods
Study Population
Patients with cancer meeting all of the following criteria were
included in the study: patients who were 18 years or older,
with a signed informed consent, who have been diagnosed for
VTE, and who has a minimum life expectancy of 6 months.
Patients meeting any of the following criteria were excluded
from the study: patients with active bleeding or at risk of
bleeding; patients who had major surgery in the last 7 days;
patients who were at high risk of PE; patients with cardiopul-
monary instability, severe systemic venous occlusion, and
thrombocytopenia (<50 000/mL); inpatients under medical
or surgical supervision; patients with low ability to commu-
nicate and for whom it is not possible to provide care at home;
patients with an INR 1.5 due to liver dysfunction, diagnosed
for cerebral vascular aneurism, active gastric, and/or duodenal
ulcer, diagnosed for bacterial endocarditis, severe renal dys-
function, unstabilized hypertension, <35 kg or 110 kg of
weight; and patients who are allergic to heparin and who have
a history of cerebrovascular event in the last 1 month.
Life-threatening cardiopulmonary instability, which is also
considered as an exclusion criterion and required hospitaliza-
tion, was defined as high-risk VTE. Patients not required hos-
pitalization because of VTE were defined as low-risk VTE and
included in the study.
Consent
Written informed consent was obtained from all patients for
participation in the study after a review of the protocol,
their responsibilities, and their rights. Consent was also
obtained for recording of their data and collection, as out-
lined in the protocol, to allow regulatory monitoring, statis-
tical analysis, and peer review presentation and publication
of the study results.
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Study Design
TREBECA is a multicenter, noninterventional, prospective,
and observational study assessing the effectiveness and
safety of long-term LMWH for the treatment of VTE in
low-risk patients with cancer and registered in the Clinical-
trials.gov with the registration number NCT02017743, and
the last time verification was on December 2013. The study
was conducted in 15 centers all around Turkey. Treatment
choice was done according to the physician’s clinical judg-
ment. Treatment of the patients with cancer diagnosed
with VTE was recorded. Patients’ recruitment period was
8 months, and patients were followed up for a period of
12 months.
Treatment and Follow-Up
The exact dose of LMWH administered subcutaneously once
or twice daily is based on the dosage scheme according to the
patient’s body weight. Patients are given labeled kits contain-
ing syringes of LMWH containing 4000 IU, 6000 IU, or 8000
IU of enoxaparin twice daily; 5000 IU, 7500 IU, or 10000 IU of
bemiparin once daily; and 10 000 IU, 14 000 IU, or 18 000 IU
of tinzaparin once daily, whichever dose is most appropriate for
their weight.
Venous thromboembolism was diagnosed depending on the
clinical and radiological evaluation. Eastern Cooperative
Oncology Group performance status (ECOG PS), a commonly
used scale in patients with cancer, which ranges from 0 (PS: 0,
being fully functional and asymptomatic) to 4 (PS: 4, being
bedridden), was evaluated clinically, laboratory tests were per-
formed, and concomitant diseases, treatments and adverse
events (AEs), if any, were evaluated and recorded. Radiologi-
cal assessments that were carried out were Doppler ultrasono-
graphy, spiral thorax computer tomography (CT), and CT
venography.
Patients were monitored during the follow-up period of 12
months with the following 5 visits: first evaluation visit (day 0
visit), day 15 visit, month 3 visit, month 6 visit, and finally
month 12 visit. In each visit, ECOG PS, concomitant medica-
tions and LMWH-associated AEs, D-dimer, and blood counts
(eg, hemoglobin, platelets) of patients were evaluated. Further-
more, Doppler ultrasound of extremities, diametrical difference
in extremities, and physical examination of patients with DVT
were carried out. Spiral thorax CT and pulmonary examination
were carried out for patients with pulmonary thromboembo-
lism. Computed tomography venography was also performed
in rare cases.
The LMWH was given for at least 3 months and was con-
tinued if the patient did not show thrombus resolution or even if
thrombosis was resolved and the patient still had high risk
factors for thrombosis. Temporary discontinuation of LMWH
therapy, if not exceeding 2 weeks, was permitted in case of
thrombocytopenia (platelet count less than 50  109/L) or
bleeding events or if the patient had to undergo any invasive
procedure. If study drug was held or missed for more than 2
consecutive weeks, then the patient was considered to have
permanently discontinued study drug.
The Primary Objectives of the Study
The primary objective of the study was the evaluation of the
effectiveness of LMWH used in the treatment of thrombosis in
patients with cancer having VTE, including early-stage throm-
bus regression (clinical and/or radiological assessment) and
VTE recurrence at a later stage (rethrombosis rate). Addition-
ally, we assessed the safety of LMWH used in the treatment of
thrombosis in patients with cancer having VTE and thus com-
pared different LMWH treatments in terms of effectiveness and
safety in the treatment of VTE in patients with cancer (based on
the rate of thrombosis regression and presence/absence of
rethrombosis).
The Secondary Objectives of the Study
Incidence of VTE, factors that affect VTE occurrence, cancer
type, and VTE site breakdown in patients with cancer having
VTE, and observation of patient compliance to LMWH treat-
ment in outpatients were established as secondary objectives of
the study.
Results
Patient Characteristics
Data for 250 patients who met the study inclusion criteria were
examined and analyzed. Of them, 239 (95.6%) patients com-
pleted their day 15 visit, 176 (70.4%) completed their month 3
visit, 130 (52.0%) completed their month 6 visit, and 91
(36.4%) completed the entire study. One hundred thirty-three
patients were treated with enoxaparin, 112 patients were
treated with bemiparin, and 5 patients were treated with tinza-
parin. The reasons and numbers of patients who discontinued
the therapy during the follow-up period were as follows: 111
patients died, 34 patients were lost to follow-up, 8 patients
failed to give informed consent for follow-up, and 2 patients
had serious AEs (eg, gastrointestinal bleeding).
The mean age of the patients was 60.2 + 13.7, while 133
(53.2%) of the patients were women. Colorectal (21.2%), lung
(16.8%), and breast (14.8%) cancers were the most common
forms of cancer. Among these patients, 200 (80%) patients had
ECOG PS 0 and 1. One hundred thirty-four patients were never
smokers, and smoking history was not available for 44 patients.
Patient characteristics are presented in Table 1.
It was determined that 173 (69.2%) patients were metastatic
at the baseline visit, 80% (n ¼ 200) had previous or ongoing
chemotherapy, and 73 (29.2%) patients had previous or
ongoing radiotherapy. Twenty-five (10%) patients had central
catheter and 40 (16%) patients were not mobilized when throm-
bosis occurred, and only 10 patients had a history of
thrombophilia.
Thromboembolism was detected in the lower extremities in
66.8% of the patients, in 14.8% in the upper extremities, and in
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19.2% in the lung, and 8 of the patients had thrombus on the
other sites. The occurrence of thrombosis in the left lower
extremity was 1.7 times more compared to the right lower
extremity. The occurrence of thrombosis in the right lung was
2.87 times more compared to the left lung. There was no sig-
nificant difference between the upper extremities. The most
common sites of thrombosis were lower extremities in all
malignancies (P < .05). The site of tumor and the high occur-
rence of thrombosis were as follows: the rate of thrombosis in
the lower extremity was most common among gynecological
cancers (88%), whereas the rate of thrombosis in the upper
extremity was most common in breast cancers (27.1%). The
rate of thrombosis in the lungs was most common in lung
cancers (26.2%; Table 2).
Effectiveness of LMWH
Anticoagulant therapy provoked thrombus resolution in 15
(6.3%) of the patients on day 15. The thrombosis was dissolved
in 1.5% of the patients using enoxaparin and in 11.6% of the
patients using bemiparin (P ¼ .001; Figure 1A). The LMWH
was replaced or the dose of the current drug was increased in
cases where no reductions were observed in the thrombus.
Thrombosis was dissolved in 81 more patients (46%) by month
3 visit. This ratio was 35 (43.2%) of 81 among patients taking
enoxaparin and 46 (56.8%) of 81 among patients taking bemi-
parin at the time of the third visit (P ¼ .002; Figure 1B).
Thrombosis was dissolved in 22 more patients (16.9%) by
month 6 visit. This ratio was 5 (22.7%) of 22 among patients
taking enoxaparin and 15 (68.2%) of 22 among patients taking
bemiparin at the time of the fourth visit (P ¼ .000; Figure 1C).
Thrombosis was dissolved in 5 (5.5%) more patients by month
12 visit. This ratio was 1 (20%) of 5 among patients taking
enoxaparin and 4 (80%) of 5 among patients taking bemiparin
at the time of the 12th month visit (P ¼ .026; Figure 1D).
Among 5 patients receiving tinzaparin, thrombus was resolved
in 2 patients in month 6 visit and 4 other patients discontinued
therapy during the follow-up period. The total rates for the
thrombus resolution during the 3-month and 6-month period
were 38.4% and 47.2%, respectively (Figure 2).
Allocation of LMWH treatment based on primary tumor
sites is presented in Table 3. When we evaluated the relation-
ship between primary tumor sites and thrombus resolution,
rates of thrombus resolution in breast, lung, gastric, and gyne-
cological cancers were much higher compared to the rates of
thrombus resolution in colorectal, pancreas, and urological
cancers (Table 4). Thrombus recurrence was observed in 10
patients during the follow-up period after LMWH treatment
was discontinued. Total rate of recurrence was 4.1%.
Safety of LMWH
Low-molecular-weight heparin was discontinued in only 2
patients due to gastrointestinal bleeding; aside from this, there
were no other serious drug-related AEs requiring discontinua-
tion. Both patients who had gastrointestinal bleeding had gas-
tric cancer. One of these major bleedings occurred in a patient
under bemiparin treatment and the other bleeding event was
fatal while on enoxaparin treatment (Table 5). There were no
patients with grade 3 or 4 thrombocytopenia or other AEs.
Discussion
Cancer and VTE are closely related. Indeed, cancer can reveal
VTE and VTE can be the first sign of cancer. Low-molecular-
weight heparin is now the first-line treatment in patients with
cancer.
Types of tumor associated with the highest VTE risk are
pancreatic, stomach, lung, ovarian, uterine, bladder, and brain
tumors.2 In the IMPACT study, 27 479 patients with cancer had
received chemotherapy and patients with a history of VTE
within 12 months during chemotherapy were evaluated. Rates
of VTE according to primary tumor sites were pancreas,
21.3%; stomach, 16.2%; lung, 14.8%; colorectal, 11.7%; ovary,
11.4%; and bladder, 9.8%.3 However, most common primary
Table 1. Patient Characteristics.
Mean age 60.2 + 13.7 years
Sex ratio F:M 133 (53.2%):117 (46.8%)
Cancer types, n (%)
Colorectal 53 (21.2)
Lung 42 (16.8)
Breast 37 (14.8)
Gynecological 25 (10)
Urological 24 (9.6)
Gastric 22 (8.8)
Pancreas 19 (7.6)
Other 28 (11.2)
Smoking history, n (%)
Ex smoker 49 (19.6)
Current smoker 23 (9.2)
Nonsmoker 134 (53.6)
ECOG performance status (PS), n (%)
PS 0 67 (26.8)
PS 1 133 (53.2)
PS 2 50 (20)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; F, female; M,
male.
Table 2. Rates of Thrombus Location According to Primary Tumor
Sites.
Primary Tumor Sites n
Thrombus Location, %
Lower Limb Upper Limb Lung
Lung 42 64.2 11.9 26.2
Breast 37 51.3 27.1 21.6
Colorectal 53 75.4 15.1 11.3
Stomach 22 59.1 22.7 22.7
Pancreas 19 63.1 15.8 10.5
Urological 24 62.5 16.7 20.8
Gynecological 25 88.0 0 12.0
Others 28 67.9 7.1 25.0
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tumor sites are colorectal, lung, and breast in our study. The
reason of why the VTE ratio was lower in patients with pan-
creatic cancer and stomach cancer could be the consequence of
the low number of patients.
Randomized cohort studies showed that LMWHs are
more effective, are safer, have positive contribution on sur-
vival, do not need monitoring, and drug interactions with
chemotherapeutics are less.4,8-15 Therefore, compared to VKA,
LMWHs are the treatments of choice in patients with cancer.
Low-molecular-weight heparins such as dalteparin, enoxa-
parin, tinzaparin, and bemiparin are drugs of choice for VTE
treatment and prevention, since they enable outpatient treat-
ment and eliminate the need for therapeutic monitoring in most
patients. Few clinical studies have tested whether the clinical
effects of these agents are comparable. In the literature, studies
usually compared LMWHs with VKAs. On the other hand, in
our study, LMWHs are compared to each other where there is
lack of data.
For long-term anticoagulation, LMWH is preferred for at
least 6 months. Anticoagulation with LMWH beyond the initial
6 months may be considered for selected patients with active
cancer such as those with metastatic disease or those receiving
chemotherapy.5 It is recommended that all patients should be
reassessed in 5 to 7 days to ensure symptomatic improvement
after starting LMWH.16,17 Data on the frequency of patient
evaluation who are given LMWH for the treatment of VTE
as well as the dose increments and the switch time of LMWH
were not provided. In our study, our first evaluation was on day
15, clinically and radiologically. Clinical and radiological res-
olution of the thrombus was statistically significantly higher in
patients receiving bemiparin compared to patients receiving
enoxaparin, on day 15, month 3, and month 6 visits. This could
result from the differentiated pharmacological profile of bemi-
parin compared to other LMWHs: Bemiparin has a lower mole-
cular weight than enoxaparin (3.600 vs 4.500 Da), and even it
Figure 1. A, Impact of anticoagulant therapy in the thrombus resolution in the early stages of treatment. B, Impact of anticoagulant therapy in
the thrombus resolution at month 3 visit. C, Impact of anticoagulant therapy in thrombus resolution at month 6 visit. D, Impact of anticoagulant
therapy in thrombus resolution at month 12 visit.
Figure 2. Thrombus resolution with low-molecular weight heparin
(LMWH) treatment during follow-up period.
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has the lowest molecular weight among all currently marketed
LMWHs.18 In addition to that, what determines the effective-
ness of LMWH is antithrombin activity, thus anti-factor-Xa
activity.19 Previous published studies have shown that the
anti-factor Xa–anti-factor IIa ratio of enoxaparin is between
3.3 and 5.3, whereas this ratio is 8.0 for bemiparin.18 As this
ratio increases, effectiveness/safety correlation of LMWH
might increase as well. In a study of Borrell et al, the prophy-
lactic doses of bemiparin and enoxaparin have been compared
and the serum anti-factor-Xa activity has been found to be
higher; likewise, the duration of serum anti-factor-Xa activity
has been found longer for bemiparin.20 The longer mean half-
life of 5.3 hours for bemiparin compared to 4.3 hours for enox-
aparin is another fact for bemiparin being more efficacious than
enoxaparin.18 The longer half-life provides a longer duration of
the drug in the blood, thus providing the effective dose for a
longer time. The bioavailability of the route of subcutaneous
administration of LMWH is also different. The bioavailability
of bemiparin is 96% compared to 92% of enoxaparin.21 It
might be concluded that lower molecular weight, longer half-
life, higher anti-factor-Xa activity, and higher bioavailability of
bemiparin make it more effective in the thrombus resolution in
our study.
In many previous studies, LMWHs have been proved to be
safer than warfarin. When we evaluated related studies, Meyer
et al showed that prolonged treatment with enoxaparin is safer
than with warfarin in patients with cancer.9 And the ESFERA
study indicated that bemiparin is a safer and cost-neutral alter-
native to warfarin for long-term treatment of VTE.4 In the
ESFERA study, major bleeding rate was only 0.4% in bemi-
parin group and 1.7% in warfarin group. In our study, we also
observed that major bleeding rates were very low in patients
receiving both bemiparin and enoxaparin.
Although the present research has reached its aims, there
were some limitations. First, it was not a randomized study, but
an observational study, and because of the multicenter design,
radiological imaging of the patients, the principle indicator of
the thrombus resolution, was carried out by the various radi-
ologists. Due to disease progression, some of the patients did
not respond to cancer therapies, and therefore, they did not
respond to LMWH either. Since no information is available,
of which LMWH was administered to these treatment-resistant
patients, this can be considered as a limitation of the present
observational study.
Conclusion
In conclusion, this is the first comprehensive study comparing
LMWHs, head to head, in patients with cancer having VTE.
The observation that bemiparin is more effective in resolution
of thrombosis was noteworthy. It was observed that thrombosis
could not be effectively treated within the first 15 days in a
significant portion of patients, but it can be concluded that the
effectiveness of the treatment increases after month 3. There-
fore, we can say that a treatment of at least 3 months is appro-
priate for patients with cancer, even among those with a low
risk of VTE.
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Table 3. Allocation of LMWH Treatment Based on Primary Tumor
Sites Is Presented.
Primary Tumor Sites n
Received LMWH, %
Enoxaparin Bemiparin
Lung 42 45.2 54.8
Breast 37 59.5 40.5
Colorectal 53 50.9 49.1
Stomach 22 54.5 45.5
Pancreas 19 57.9 26.3
Urological 24 66.7 33.3
Gynecological 25 44.0 52.0
Others 28 53.6 42.9
Table 4. Rates of Thrombus Resolution in Evaluated Patients Accord-
ing to Primary Tumor Sites.
Primary
Tumor Sites Day 15 Month 3 Month 6 Month 12
Lung 7.1% (3/42) 61.3% (19/31) 5.5% (1/18) 0% (0/9)
Breast 10.8% (4/37) 53.8% (14/26) 22.7% (5/22) 11.8 (2/17)
Colorectal 3.8% (2/52) 34% (16/47) 13.5% (5/37) 8.3% (2/24)
Stomach 10% (2/20) 66.7% (10/15) 11.1% (1/9) 0% (0/5)
Pancreas 0% (0/17) 33.3% (2/6) NE NE
Urological 0% (0/22) 35.3% (6/17) 15.4% (2/13) 0% (0/11)
Gynecological 8.7% (2/23) 58.8% (10/17) 14.3% (2/14) 10% (1/10)
Abbreviation: NE, not evaluated.
Table 5. LMWH Adverse Events.
Bemiparin Enoxaparin
Major bleeding 1 (0.89%) 1 (0.75%)
Minor bleeding 0 (0.0%) 1 (0.75%)
Abbreviation: LMWH, low-molecular-weight heparin.
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